Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
brain disease
Biotech
Ovid pauses ph. 2 plans for ROCK2 inhibitor to mull rival's data
Ovid is pumping the brakes on a planned phase 2 trial in a type of brain lesion while it considers any lessons from Recursion’s rival candidate.
James Waldron
Nov 13, 2024 8:15am
Recursion's brain disease trial shows scant evidence of efficacy
Sep 3, 2024 10:30am
Super-fit mice reveal anti-inflammatory brain protein
Dec 10, 2021 8:40am
Brain atlas unveils dozens of cell types that control movement
Oct 11, 2021 8:44am
Omniscient Neurotechnology rakes in $29M for brain-mapping tech
Jul 20, 2021 9:45am
Ovid plans to shop with Takeda bucks after shedding lead asset
Apr 22, 2021 9:50am
